Glenmark receives final approval by MHRA for Maloff Protect

04 Jul 2017 Evaluate

Glenmark Pharmaceuticals Europe (Glenmark) has been granted final approval by the Medicines and Healthcare products Regulatory Agency (MHRA) for Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets), anti-malarial medication, as a pharmacy license in the United Kingdom. Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets) is the first OTC approval granted by the MHRA.

Maloff Protect will be used in the prevention of malaria in adults travelling to areas where malaria is prevalent. Maloff Protect contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK. Under this approval, patients will be able to purchase Maloff Protect without a prescription.

Glenmark’s current portfolio consists of +100 SKUs authorized for distribution in the UK, both in-licensed as well as Glenmark’s own products. In addition to this approval Glenmark UK continues to identify and explore both internal as well as external development partnerships to supplement and accelerate the growth of its existing opportunities and future portfolio.


Glenmark Pharma Share Price

2013.40 26.65 (1.34%)
30-Jan-2026 13:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1602.00
Dr. Reddys Lab 1215.00
Cipla 1324.00
Zydus Lifesciences 886.30
Lupin 2145.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×